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Abstract
Clinically, combined therapy of cisplatin (CDDP) and metformin is an effective treatment for non-
small cell lung cancer (NSCLC). The success is attributed to synergistic effects between the two 
drugs. Therefore, we hypothesize that co-encapsulation of CDDP and metformin will avoid the 
prominent toxicity of CDDP while maintaining the synergy between the regimens. CDDP was first 
conjugated to polyglutamic acid (PGA) to form anionic PGA-CDDP which was electrostatically 
complexed with the cationic polymeric metformin (polymet). The nano-sized complex was then 
stabilized with cationic liposomes composed of DOTAP (2, 3-Dioleoyloxy-propyl)-
trimethylammonium/Cholesterol/DSPE-PEG-anisamide aminoethyl. Both in vitro and in vivo 
experiments confirmed the synergy between polymet and CDDP. CDDP delivered with 
nanoparticles (NPs) exhibited significantly increased tumor accumulation over free CDDP and 
suppressed tumor growth through apoptosis in NSCLC H460 tumor-bearing mice without 
nephrotoxicity. The synergistic effect of polymet alongside CDDP demonstrates that polymet-
CDDP NPs can activate the AMP-activated protein kinase α (AMPKα) pathway and inhibit 
mammalian target rapamycin (mTOR) activity to enhance growth suppression. In all, this platform 
is the first to successfully co-load polymet, a polymeric metformin, and CDDP into the same 
nanoparticle for successful treatment of NSCLC.
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1. Introduction
Lung cancer remains the leading cause of cancer-related deaths worldwide, and about 85% 
of all lung cancers are non-small cell lung cancer (NSCLC) [1,2]. The overall 5-year 
survival rate for patients with NSCLC is 13% in Europe and 16% in the United States [3,4]. 
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Thus, the efficacy and success rate of treatment needs improvement. Cisplatin (CDDP) 
remains the leading therapy for advanced NSCLC [5]. For patients with advanced (stage III 
and IV) NSCLC, CDDP was often used in combination with paclitaxel, gemcitabine, 
docetaxel, vinorelbine or irinotecan, in concurrence with radiotherapy [6].
Recent studies have shown that in addition to the therapies listed above, metformin, a 
common antidiabetic drug (N′,N′-dimethylbiguanide), displayed significant growth-
inhibition and proapoptotic effects in several cancers, including NSCLC [7,8]. Metformin 
activates AMP-activated protein kinase (AMPK), inhibits the mammalian target of 
rapamycin (mTOR) and down-regulates excision repair cross-complementation group 1 
(ERCC1) [9,10]. Consequently, metformin may be used in combination with CDDP to treat 
NSCLC [11,12].
While preclinical studies of free CDDP and metformin in combination exhibited promising 
outcomes, the clinical application of this combination is severely restricted by a collection of 
issues. Firstly, CDDP and metformin are administered through different routes, i.e. oral for 
metformin and intravenous (IV) injection for CDDP, which challenges patient compliance. 
The difference in administrative routes leads to a subsequent discrepancy in the 
pharmacokinetic (PK) profiles. Second, proper evaluation of the synergy between these two 
drugs is further complicated by the different physicochemical properties of the drugs, which 
leads to subpar anti-tumor efficacies. Furthermore, well-known toxicities such as nephro and 
neurotoxicity limit the use of CDDP. Thus, formulating these two drugs into a single 
nanoparticle will be a promising strategy to treat NSCLC and overcome the aforementioned 
limitations.
Formulating CDDP into nanoparticles (NPs), such as liposomal or polymeric formulations, 
significantly reduces the adverse side effects of CDDP while maintaining its anti-tumor 
efficacy [13,14]. This advantage can be partially attributed to the fact that NPS can be 
modified to avoid undesired uptake by the reticuloendothelial system (RES), leading to 
prolonged blood circulation and increased tumor accumulation. Due to promising preclinical 
studies, several NPs incorporating CDDP have already been approved for clinical trials, such 
as Lipoplatin [15] and Nanoplatin [16]. However, unlike the co-delivery of CDDP with other 
hydrophobic drugs, which works by modifying CDDP into hydrophobic platinum IV 
prodrugs, co-delivery of CDDP with a hydrophilic drug (e.g. metformin) has rarely been 
reported [17]. Herein, we report a novel strategy for the co-encapsulation of CDDP and 
metformin into a single self-assembled core-membrane NPs. We took advantage of recently 
discovered polymeric metformin (polymet) which exhibits similar anticancer efficacy as 
metformin and acts through the same mechanistic pathway [18]. Namely, polymet both 
activates the AMPK pathway, and reduces mTOR activation. It is appropriate to consider 
polymet as a substitute for metformin. CDDP was chemically conjugated to polyglutamic 
acid (PGA) through the displacement of chlorine atoms by hydrogen of carboxyl groups on 
PGA side-chains to form anionic PGA-CDDP as reported before [14,19]. From here, 
cationic polymet was then subject to an electrostatic interaction with an anionic PGA-CDDP 
conjugates to produce a negatively charged core which was then coated with PEGylated 
cationic liposomes to form the final core-membrane structure. The dissociation of polymeric 
ion pairs then controls the release of both therapeutic moieties.
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Herein we report the synergistic anti-cancer activity of NPs containing both polymet and 
PGA-CDDP. The experiments were carried out in H460 human lung cancer xenograft as a 
model for human NSCLC.
2. Materials and methods
2.1. Chemicals and materials
CDDP was purchased from Sigma-Aldrich (Dorset, UK). Linear polyethylenimine (PEI) 
hydrochloride with average molecular weight 8000, Poly-L-glutamic acid sodium salt 
(molecular weight 3000–15,000), cholesterol, dicyandiamide, p-Anisic acid, Ethylene 
dichloride (EDC), N-Hydroxysuccinimide (NHS), 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT), N,N-Diisopropylethylamine (DIPEA), Radio-
Immunoprecipitation Assay (RIPA), dichloromethane and silver nitrate were obtained from 
Sigma-Aldrich (St Louis, MO) without further purification. (2, 3-Dioleoyloxy-propyl)-
trimethylammonium (DOTAP) and 1, 2-distearoryl-sn-glycero-3-phosphoethanolamine-N 
[methoxy (polyethyleneglycol-2000)] (ammonium salt) (DSPE-PEG2000) were purchased 
from Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG-aminoethyl anisamide (DSPE-
PEG-AA) was synthesized in our lab as described previously [20]. TdT-dependent dUTP-
biotin nick end labeling (TUNEL) assay kits was obtained from Promega (Madison, WI). 4′,
6-diamidino-2-phenylindole (DAPI) was obtained from Vector laboratories (Burlingame, 
CA). Bicinchoninine acid (BCA) protein assay reagent kit was purchased from Thermo 
Fisher Scientific Inc. Rabbit monoclonal antibodies: Phospho-AMPKα (Thr172) (40H9), 
AMPKα (D5A2), Phospho-mTOR (Ser2448) (D9C2) XP®, mTOR (7C10), Phospho-p70 
S6 Kinase (Ser371), Phospho-4E-BP1 (Thr37/46), and horseradish peroxidase (HRP)-linked 
Antibody were purchased from Cell signaling. Reduced glyceraldehyde-phosphate 
dehydrogenase (GAPDH) (14C10), mouse monoclonal antibodies: ERCC1 (3H11), anti-
rabbit IgG, xeroderma pigmentosum complementation group A (XPA) (12F5), poly ADP-
ribose polymerase-1 (PARP-1) (F-2) and goat antimouse-IgG2b, HRP-linked Antibody were 
purchased from Santa Cruz Biotechnology, Inc.
2.2. Cell lines and experimental animals
H460 human NSCLC cells was obtained from American Type Culture Collection (ATCC) 
and was cultured in RPMI 1640 Media (Sigma Aldrich, UK) supplemented with 10% fetal 
bovine serum (Life Technologies, Carlsbad, California), 100 U/mL penicillin, and 100 
μg/mL streptomycin (Invitrogen). Cells were cultivated in a humidified incubator at 37 °C 
with 5% CO2 and harvested with 0.05% trypsin-EDTA (ethylene diamine tetraacetic acid) 
before subculture.
Female nude mice of 6–8 weeks old were purchased from National Cancer Institute 
(Bethesda, MD) and bred by the Division of Laboratory Animal Medicine (DLAM) at 
University of North Carolina at Chapel Hill. To establish the xenograft models, 5 × 106 
H460 cells in 100 μL of phosphate-buffered saline (PBS) were inoculated subcutaneously 
into the right flank of each mouse. All procedures involving experimental animals were 
performed in accordance with the protocols approved by the University of North Carolina 
Xiong et al. Page 3
J Control Release. Author manuscript; available in PMC 2017 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Institutional Animal Care and Use Committee and conformed to the Guide for the Care and 
Use of Laboratory Animals (NIH publication No. 86-23, revised 1985).
2.3. Preparation of polymet
Polymet (ca. molecular weight is 4300 Da) was synthesized as previous reported [18]. 
Briefly, 0.2 g of linear PEI and 2 g of dicyandiamide were mixed in 10 mL deionized water. 
Two milliliters HCl were added into the solution (Fig. 1A). The compounds reacted in a 
100 °C oil bath for 4 h. Polymet was then purified through an ultrafiltration tube with a 
cutoff of 3000 Da, washed with deionized water for two times and lyophilized.
2.4. Preparation and characterization of polyglutamic acid-CDDP conjugation (PGA-CDDP)
The preparation of PGA-CDDP was synthesized as previous reported [19]. First the cis-
[Pt(NH3)2(H2O)2] (NO3)2 precursor was as previously described [21]. Briefly, AgNO3 (66.2 
mg or 0.39 mmol) was added to a suspension of CDDP (60 mg or 0.2 mmol) in 1 mL water. 
The mixture was heated at 60 °C for 3 h and then stirred overnight in a flask protected from 
light with aluminum foil. The mixture was centrifuged at 16,000 rpm for 15 min to 
precipitate AgCl. The supernatant was then filtered using a 0.22 μm syringe filter to afford 
the desired product (CDDP precursor). PGA was solved in deionized water (25 mM) and 
then added to the solution of CDDP precursor (6.25 mM) at the same volume. The mixture 
was then put in dark at room temperature for 72 h with gently stirring to form the PGA-
CDDP conjugation (Fig. 1B). The formation of the conjugation was certified by the 1H 
NMR nuclear magnetic resonance (1H NMR) (Fig. S1).
2.5. Preparation and characterization of the NPs
The formulation of polymet-CDDP NPs involves two key steps after the production of PGA-
CDDP. Firstly, an anionic core must be formed from a complex of polymet and PGA-CDDP. 
The anionic core is then combined with cationic liposomes composed of DOTAP and 
cholesterol to produce the outer membrane of the core-membrane structure (Fig. 1C).
2.5.1. Preparation of cores—In optimizing polymet-CDDP NPs, the core should be 
composed of a ratio of polymet to PGA-CDDP to yield the smallest anionic NPs. So, 200 μL 
of PGA-CDDP (3.1 mM CDDP) and various volume of polymet solution (12.5 mM) were 
mixed at different ratios (1∶0.6, 1∶0.8, 1∶1, 1∶1.2) by pipetting up and down and allowed to 
stand at room temperature for 10 min before the size and zeta potential are determined. The 
optimal ratio of the complex was determined by the particle size and zeta potential results 
determined by dynamic light scattering (DLS) using a Malvern ZetaSizer Nano series 
(Westborough, MA). After the optimal ratio of the core was chosen, the core was mixed with 
cationic DOTAP/cholesterol liposomes and incubated for another 10 min for lipid coating.
2.5.2. Preparation of the lipid membrane—To prepare the lipid membrane, the 
DOTAP (20 mM, 1 mL) and cholesterol (20 mM, 1 mL) were dissolved (1∶1 mol/mol) in 
chloroform and the solvent was removed under reduced pressure. The lipid film was 
hydrated overnight with 1 mL distilled water to form cationic liposomes (20 mM), which 
were sequentially extruded through polycarbonate membranes (200 nm × 20 times and 50 
nm × 20 times) (Millipore, Bil-lerica, MA).
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2.5.3. Preparation of the NPs—To determine the optimal amount of DOTAP/cholesterol 
liposomes for the core, different ratios (8∶1, 10∶1, 12∶1) of liposome to PGA-CDDP 
conjugates were designed. The optimal NPs were defined as the ratio that yielded the 
smallest particle size, smallest polydispersity index (PDI) and appropriate cationic charge. 
Furthermore, previous studies have shown that H460 cells exhibited over expression of 
sigma receptors [22]. Therefore, aminoethyl anisamide, was specifically employed as 
targeting moiety to sigma receptors to direct polymet-CDDP NPs to the H460 tumors. The 
lipid-coated NPs were PEGylated using a post-insertional approach by adding 15 μL DSPE-
PEG (50 mg/mL) and 15 μL DSPE-PEG-AA (50 mg/mL) and incubated with NPs at 50 °C 
for 15 min. The ratio of DOTAP∶DSPE-PEG∶DSPE-PEG-AA was maintained as 
(1∶0.12∶0.11).
The preparation of PEI-CDDP NPs followed the same procedure as polymet-CDDP NPs 
except polymet was replaced with PEI (12.5 mM). Also polymet NPs was prepared 
following the same procedure as polymet-CDDP NPs except replacing PGA-CDDP with 
PGA.
2.5.4. Characterization of the NPs—The size distribution and the zeta potential of 
particles were deter mined using a Malvern ZetaSizer Nano series (Westborough, MA). 
Transmission electron microscope (TEM) images of polymet-CDDP NPs were acquired 
through the use of JEOL 100CX II TEM (Tokyo, Japan). Briefly, freshly prepared polymet-
CDDP NPs (20 μL) were carefully dropped onto a 300-mesh carbon-coated copper grid (Ted 
Pella, Inc., Redding, CA) and allowed to stand at room temperature for 15 min and then 
removed the assess liquid using a dry filter paper. Images were acquired at an accelerating 
voltage of 100 kV.
2.6. Cellular uptake study in H460 cell lines
H460 cells were seeded into a 12-well plate (1.5 × 105 cells/well) containing 1 ml of media. 
Twenty hours later, 1 ml of the free CDDP, PGA-CDDP, polymet-CDDP NPs, PEI-CDDP 
NPs at a concentration of 10 μM CDDP were incubated with cells in a serum-free medium. 
Four hours later, cells were treated with 0.05% trypsin-EDTA (Sigma-Aldrich) and the cell 
lysate was centrifuged at 14,000 rpm for 20 min at 4 °C to collect cells and then the cells 
were digested with HNO3. The concentration of CDDP was measured using inductively 
coupled plasma mass spectrometry (ICP-MS).
2.7. In vitro release of CDDP
The dialysis technique was employed to study the in vitro release of CDDP from free CDDP, 
PGA-CDDP, polymet-CDDP NPs, PEI-CDDP NPs in phosphate buffered saline (PBS) (pH 
7.4 with 100 mM NaCl) at 37 °C. Five hundred microliters free CDDP, PGA-CDDP, 
polymet-CDDP NPs, PEI-CDDP NPs, with 180 μg/mL CDDP separately were added into 
the dialysis tube with a molecular weight cut off of 3000 Da and dialyzed against 15 mL 
PBS in a thermo-controlled shaker with a stirring speed of 100 rpm at 37 °C for up to 144 h. 
At each predetermined time point, 300 μL samples were withdrawn and replaced with fresh 
media. The CDDP concentration was then determined by ICP-MS at specified times. All 
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experiments were performed in triplicate and the data were reported as the mean ± SEM of 3 
individual experiments.
2.8. In vitro cell viability on H460 cells and analysis of synergistic drug combinations
An MTT assay was conducted to evaluate in vitro viability of free CDDP, PGA-CDDP, 
polymet-CDDP NPs, polymet NPs and PEI-CDDP NPs in which the molar ratio of CDDP to 
polymet or PEI was 1 to 1. In brief, H460 cells were seeded in 96-well plates at a density of 
2000 cells per well 24 h prior to drug treatment. Subsequently, cells were treated with free 
drugs and the drug combination with various molar ratios at a series of dilutions in full 
medium. Following 48 h of treatment, MTT (20 μL, 5 mg/mL) reagent was added for an 
additional 4 h incubation period at 37 °C. The medium was discarded, the formed formazan 
salt was dissolved in 100 μL of DMSO and absorbance was read at 570 nm using a 
multidetection microplate reader (Plate CHAMELEON ™ V-Hidex). Cell survival rates were 
calculated as normalized to untreated control wells. Each concentration was tested in 5 wells 
and data presented as mean ± SEM. The mean drug concentration required for 50% growth 
inhibition (IC50) was determined with CompuSyn software (Version 1.0, Combo-Syn Inc., 
U.S.) using the median effect equation: Fa = [1 + (IC50 / D)m]−1, where Fa is the fraction of 
affected cells, D is drug concentration and m is the Hill slope.
Combination Index (CI) Analysis of free CDDP combined with polymet based on the Chou 
and Talalay method [23] was conducted using CompuSyn software. Briefly, for each level of 
Fa, the CI values for CDDP and polymet combinations were calculated according to the 
following equation: CI = (D)1 / (Dx)1 + (D)2 / (Dx)2, where (D)1 and (D)2 are the 
concentrations of each drug in the combination resulting in Fa × 100% growth inhibition, 
and (Dx)1 and (Dx)2 are the concentrations of the drugs alone resulting in Fa × 100% growth 
inhibition. CI values for drug combinations were plotted as a function of Fa. CI values less 
than 1 or more than 1 demonstrate synergism or antagonism of drug combinations, 
respectively. Notably, CI values between Fa 0.2 to 0.8 are considered validate [24].
2.9. Biodistribution of CDDP in tumors and other major organs in H460 tumor–bearing 
mice
H460 tumor–bearing mice were administered a single dose of free CDDP, polymet-CDDP 
NPs and PEI-CDDP NPs at the dose of 2.5 mg/kg CDDP. Each group contained 4 mice, 
which were sacrificed 24 h following IV administration. About 30 mg tumor and tissue 
samples (heart, liver, spleen, lung, and kidney) were digested with 300 μL 60% nitric acid 
(Acros Organic) at 60 °C overnight and proceeded to quantify CDDP by ICP-MS. The 
uptake of CDDP was expressed as the percentage of the injected dose per gram tumor or 
tissue.
2.10. Anti-tumor efficacy in H460 human NSCLC xenografts
Human NSCLC xenografts were used as previously described [18,22]. H460 cells (5.0 × 
106) were subcutaneously injected into the right flanks of female athymic nu/nu mice. On 
day 8 after tumor implantation (tumor size 60–80 mm2), mice were randomized into 5 
groups (n = 4–6) as follows: untreated control (PBS), free CDDP, polymet NPs, polymet-
CDDP NPs and PEI-CDDP NPs. IV injections were performed every second day for a total 
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of 5 injections with CDDP dose of 2.5 mg/kg and/or the corresponding amount of polymet 
as determined by the ratio in the ultimately optimizing formulation. Animal body weight and 
tumor volumes were measured each day. The tumor length (L) and width (W) were used to 
calculate volume (V) by the equation: V = 1/2 × L × W2. Mice were sacrificed the second 
day after the last injection by CO2 asphyxiation and tumors were excised.
2.11. TUNEL assay
Slides were deparaffinized through xylene and a graded alcohol series and prefixed with 4% 
formaldehyde. Apoptosis in situ was then detected by a TUNEL assay using an apoptosis 
detection kit according to the manufacturer’s instructions. Slides were then rinsed with PBS 
and mounted to a cover slip using Vectashield. All staining was evaluated and digital images 
were acquired by Eclipse Ti-U inverted microscope (Nikon Corp., Tokyo, Japan) at 20× 
magnification. Five randomly selected microscopic fields were quantitatively analyzed on 
Image J.
2.12. Serum biochemical value analysis and hematology assay
After 5 injections, the whole blood was collected and centrifuged at 4000 rpm for 5 min to 
obtain the serum. Blood urea nitrogen (BUN), creatinine, serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels were assayed as indicators of renal and 
hepatic function. Whole blood was collected for the detection of myelosuppression by 
counting the Red blood cells (RBC), white blood cells (WBC), platelets (PLT), hemoglobin 
(HGB) and hematocrits (HCT). Organs (heart, liver, spleen, lung, and kidney) were fixed 
with 4% PFA and sectioned for H&E staining to evaluate organ-specific toxicity.
2.13. Western-blot analysis
2.13.1. Western-blot analysis in tumor of H460 bearing mice—Twenty-four hours 
after 5 times IV injections, H460 bearing mice were sacrificed and tumor lysates were 
prepared as previously described [25]. Briefly, tumor samples of each group were lysed with 
RIPA buffer supplemented with 1% protease inhibitor cocktail (PIC). Protein concentration 
in the tumor or cell lysate was determined using a BCA protein assay according to the 
manufacturer’s instruction (Invitrogen). Then 40 μg of protein per lane was separated by 4–
12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE 
electrophoresis) (Invitrogen) before being transferred to polyvinylidene difluoride (PVDF) 
membranes (Bio-Rad). The membranes were blocked for 1 h with 5% Bovine Serum 
Albumin (BSA) at room temperature and then incubated overnight at 4 °C with and then 
incubated with primary antibodies overnight at 4 °C. The membranes were washed 3 times 
and then incubated with a secondary antibody (1∶4000 dilution) at room temperature for 1 h. 
Finally, the membranes were washed 4 times and developed using a chemiluminescence 
system according to the manufacturer’s instructions (Thermo Scientific). GAPDH antibody 
(1∶2000 dilution) was probed as the loading control. The membranes were washed 3 times 
and then incubated with a Rabbit anti-mouse secondary antibody (1∶4000 dilution) or an 
Anti-rabbit IgG, HRP-linked Antibody (1∶4000 dilution) at room temperature for 1 h. 
Finally, the membranes were washed 4 times and developed by an enhanced 
chemiluminescence system according to the manufacturer’s instructions (Thermo 
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Scientific). The relative protein expression level was quantified with Image J software 
(National Institutes of Health, Bethesda, MD).
2.13.2. Western-blot analysis in vitro—H460 cells were seeded into a 6-well plate (5 × 
105 cells/well) containing 2 ml of media. Twenty hours later, 2 ml of free CDDP (1 μM, 10 
μM), polymet (1 μM, 10 μM), and their combo at the molar ratio of 1∶1 were incubated with 
cells in a RPMI 1640 medium. Twenty-four hours later, cells were treated with RIPA buffer 
and the cell lysates were quantified for the protein concentration by BCA. Forty micrograms 
of protein per lane was separated by 4–12% SDS-PAGE electrophoresis before being 
transferred to PVDF membranes. The subsequent procedure was as indicated above.
2.14. Statistical analysis
Quantitative data were expressed as mean ± SEM. The analysis of variance was completed 
using a one-way Analysis of Variance (ANOVA). P < 0.05 was considered statistically 
significant. All statistical analyses were carried out using GraphPad Prism Software (Version 
6.0, GrapPad Software, San Diego, CA).
3. Results and discussions
3.1. Preparation of polymet-CDDP NPs
3.1.1. Preparation of polymet—Polymet was synthesized successfully as previous 
reported [18] (Fig. 1A). The matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI-TOF-MS) results indicated the modification of PEI by 
dicyandiamide. Additionally, polymet displayed a significantly lower cytotoxicity measured 
using a MTT assay with a 3-fold increase in maximum tolerable dose (MTD) compared to 
PEI on H460 cells. These results indirectly indicated the conversion of the secondary amine 
of PEI to polymet [18].
3.1.2. Preparation of PGA-CDDP—CDDP was chemically conjugated PGA through the 
substitution of hydrogen atoms on the carboxyl groups of PGA side-chains (Fig. 1B). The 
free CDDP and water-soluble conjugate, PGA-CDDP, were both quantified via ICP-MS. To 
ensure reaction completion, the product was subject to ultrafiltration with a 3000 Da cutoff 
membrane. The supernatant was analyzed for any traces of unreacted free CDDP. Findings 
confirmed a ~100% reaction yield after 72 h of stirring (Fig. S1) and 1H NMR results further 
confirmed the successful manufacture of PGA-CDDP (Fig. S1).
3.1.3. Preparation and optimization of polymet-CDDP NPs—As Fig. 2A 
demonstrated, 1∶1 polymet∶CDDP produced the smallest cores (132 ± 2 nm) with a zeta 
potential of (−36 ± 1 mV). The anionic inner core composed of a 1∶1 polymet∶PGA-CDDP 
was then subject to electrostatic interactions with cationic DOTAP/cholesterol liposomes. 
Considering the parameters of defining the nanoparticle mentioned in Section 2.5.3, 10∶1 
DOTAP/cholesterol liposome to CDDP molar ratio was chosen as the optimal and yielded 
NPs with sizes of 145 ± 1 nm, zeta potentials of 49 ± 1 mV (Fig. 2B) and PDI of 0.2. After 
introducing DSPE-PEG and DSPE-PEG-AA into the NPs, the final NPs were formed. The 
size, PDI and the zeta potential of both cores and the final NPs were summarized in the 
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Table 1 and final NPs had an approximate diameter of 150 nm and positive surface charge of 
about 50 mV.
Despite a cationic surface charge, Fig. S4 and S5 demonstrated that NPs induced no 
significant toxicities on healthy tissues of the heart, liver, spleen, lung and kidney tested in 
vivo. Furthermore, no significant deviations in hematological parameters and serum 
biochemistry were found in NP treated groups. These findings confirmed that NPs had no 
observable toxicities on normal tissues despite their cationic charge, which can most likely 
be attributed to the PEG shielding effect of the PEGylated NPs. Additionally, a recently 
published manuscript found that PEGylated DOTAP particles with similar surface charges 
and NP structure, had low toxicity on normal lung fibroblasts MRC-5, further confirming the 
minimal toxicity properties of the blank NPs [26].
Polymet and PGA-CDDP were condensed into the solid core due to electrostatic interaction. 
The zeta potential of the core is negative, so, it is reasonable to assume the encapsulation 
efficiency of the cationic polymet is approximately 100%. The negative core was further 
coated with an excess of liposomes, to produce a final cationic charge. Similarly, the 
encapsulation of the anionic PGA-CDDP should be around 100%. Our lab has previously 
investigated that in lipid-polycation nanoparticles, the core was coated by two cationic lipid 
bilayers which were the inner bilayer stabilized by charge–charge interaction and the outer 
layer. When 10.6 mol% of DSPE-PEG2000 presented on the particle surface, approximately 
60% of the total cationic lipids which located in the outer bilayer, were stripped off during 
the PEGylation [27]. So, we calculated the loading capacity of both polymet and CDDP with 
their actual weights according to their ratio in the NPs excluding the excess lipids. The 
loading ratio of CDDP and polymet were about 2.5% and 1.1% respectively.
Imaging by TEM revealed polymet-CDDP cores as mono-dispersed spheroids with a 
diameter of approximately 50 nm (Fig. 2C), which was smaller than the value measured by 
DLS (average 130 nm). This significant discrepancy is to be expected, as the size determined 
through DLS regards the hydrodynamic size, which includes both solvent (hydro) and shape 
(dynamic) effects of the NPs, while TEM just reveals the size of the core [28,29] (Fig. S2). 
Due to the water solubility and ionic complex of PGA-CDDP to polymet, the hydrodynamic 
diameter is expected to be larger than the dehydrated diameter determined by TEM (Table 
1).
3.2. In vitro Cellular uptake of NPs in H460 tumor cells
In vitro cellular uptake studies showed that polymet-CDDP NPs and PEI-CDDP NPs shared 
comparable NP uptake profiles when measuring Pt content in H460 cells (Fig. 3A). 
However, the uptake of both aforementioned NP platforms was significantly higher than the 
uptake of either free CDDP or PGA-CDDP on H460, and can be attributed to the cationic 
lipid coating along with the active targeting capabilities of aminoethyl anisamide. The 
results from these preliminary studies serve to confirm the efficient cellular uptake of 
polymet-CDDP NPs.
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3.3. In vitro CDDP release from NPs
The release of CDDP was determined by dialyzing the NPs and PGA-CDDP conjugate 
against a buffer containing 10 mM phosphate (pH 7.4) and 100 mM NaCl at 37 °C through a 
membrane with a cutoff size of 3000 Da (Fig. 3B). This particular size was selected as 
membrane pores are large enough to allow diffusion of free CDDP but not NPs or the PGA-
CDDP conjugate. The mechanism of CDDP release occurred through an exchange reaction 
between the chloride and carboxylate groups of PGA in the conjugate [30] and released 
CDDP was quantified via ICP-MS. Results demonstrated similar release patterns (40% 
cumulative release) for PGA-CDDP conjugate, polymet-CDDP NPs and PEI-CDDP NPs 
over 72 h. Significant deviations in release did not occur until after 144 h. However, 
molecular CDDP was quickly cleared through the membrane after just 6 h. These results 
indicate that the PGA conjugated to CDDP was the main mechanism responsible for 
prolonged drug release.
In addition to their low toxicity to normal tissues, lipid coated polyplexes were shown to be 
stable both in vitro and in vivo [18,31]. Using 11.5 mol% of DSPE-PEG coating, the 
majority of particles showed RES evasion; subsequently promoting delivery of the 
therapeutic agent to neoplasms. In vitro release of platinum from the NPs revealed a 
sustained release profile of CDDP, and no burst release was observed. Overall, NPs 
demonstrated high stability in physiological conditions (Fig. 3B).
3.4. Analysis of synergistic drug combination effects of and in vitro cell viability on H460 
cells
In vitro studies of the synergy between free CDDP and polymet using the Chou-Talalay 
method [23] indicated that the combination exhibited a strong synergy at a wide range of 
CDDP/polymet ratios. This range spans from 2∶1 to 1∶6 with respect to the CDDP∶polymet 
molar ratio calculated according to the number of metformin units in polymet. Throughout 
this range, the CI at the predetermined IC50 for each drug was below 0.5, indicating that any 
ratio within this range is suitable for synergy (Fig. 4A).
The synergistic effects of CDDP and polymet combinations could be further confirmed by 
the analyzing the combination’s IC50 on H460. Although the release of CDDP from PGA-
CDDP is expected to cause a subsequent increase IC50 over molecular CDDP, any increase 
can most likely be attributed to low uptake and slow CDDP release from the conjugate. 
However, in vitro viability studies indicated that integration of PGA-CDDP into NPs 
significantly reduced the IC50 to values comparable of free CDDP (Fig. 4B). These results 
could be attributed to the previous cell uptake studies which confirmed that polymet-CDDP 
NPs and PEI-CDDP NPs exhibited significantly increased cellular uptake over free CDDP 
and PGA-CDDP. Therefore, the increased uptake could compensate for the slow release of 
CDDP from the NPs.
The IC50 values of polymet and polymet NPs were 373 ± 3 μM and 35 ± 1 μM, respectively, 
which offered no significant reduction compared to free CDDP and further confirms the 
synergy between PGA-CDDP and polymet.
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3.5. Polymet-CDDP NPs inhibited tumor growth in vivo on H460 lung cancer xenograft 
model and triggered significant tumor cell apoptosis
Athymic nude mice bearing subcutaneous H460 xenografts were treated with 5 times IV 
injections of the selected treatment. Treatments include PBS, PEI-CDDP NPs, polymet NPs, 
free CDDP, or polymet-CDDP NPs (n = 4–6 per group). The dose for mice receiving 
treatment was 2.5 mg/kg with respect to CDDP and/or the corresponding amount of polymet 
as determined by the 1∶1 ratio mentioned in Section 3.1.3. As shown in Fig. 5A, polymet-
CDDP NPs, free CDDP, polymet NPs and PEI-CDDP NPs exhibited significant tumor 
growth inhibition effects when compared with PBS control group. There was no significant 
difference of antitumor efficacy between polymet NPs and PEI-CDDP NPs. However, 
polymet-CDDP NPs exhibited comparable efficacy with free CDDP and significantly 
improved anti-cancer efficacy over PBS, PEI-CDDP NPs and polymet-NPs. Tumor volumes 
at the end of the study comparable between the polymet-CDDP NPs and the free CDDP 
group (Fig. 5B). This result demonstrates that polymet-CDDP NPs were able to induce 
similar degrees of efficacy compared to free CDDP. Tumor cell apoptosis was quantified via 
a TUNEL assay after treatment as shown in Fig. 5C. Free CDDP and polymet-CDDP NPs 
treated cells showed a comparable number of apoptotic cells, which are significantly more 
than the PBS and other control groups. This finding correlates with the tumor inhibition data 
shown in Fig. 5A. While there was not a significant difference in cell apoptosis between 
polymet NPs and PEI-CDDP NPs, both groups showed significantly more apoptotic cells 
than the PBS group. This suggests that polymet alone acts as a competent anticancer agent 
and plays a critical role in the overall synergy. While polymet-CDDP NPs exhibited 
comparable efficacy as free CDDP, they did not induce adverse effects on other tissues as in 
the case of free CDDP.
Fig. 5D, E and F indicated that mice treated with polymet-CDDP NPs exhibited significantly 
reduced toxicities as illustrated by BUN and creatinine levels, body weight, and 
hematoxylin-eosin (H&E) staining of kidney tissues. Primarily, polymet-CDDP NPs 
successfully mitigated the well-documented nephrotoxicity that currently limits the clinical 
use of CDDP while still maintaining an anti-cancer efficacy comparable to CDDP. These 
results indicated that while the CDDP released from polymet-CDDP NPs exhibited slow 
release, the synergy between CDDP and polymet promoted enhanced antitumor efficacy 
over PEI-CDDP NPs.
3.6. In vivo polymet-CDDP NPs accumulation in tumors and other major organs of H460 
tumor–bearing mice
It was postulated that polymet-CDDP NPs were able to achieve comparable antitumor 
efficacy as molecular CDDP despite its slow release for two reasons. Firstly, the synergistic 
effect between polymet and CDDP compensated for slow release with enhanced potency. 
Secondly, polymet-CDDP NPs were able to deliver CDDP into the tumor more efficiency 
than free CDDP. This second advantage is two tiered. Data in Fig. S3 firstly indicated that 
tumors treated with polymet-CDDP NPs and PEI-CDDP NPs exhibited significantly higher 
levels of platinum than tumors treated with free CDDP. This can most likely be attributed to 
the enhanced permeability and retention (EPR) effect of the tumor vasculature [32]. In 
addition, previously conducted cell uptake studies indicated that both polymet-CDDP NPs 
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and PEI-CDDP NPs exhibited greater cellular uptake, most likely attributed to the 
employment of sigma receptor mediated targeting. Therefore, polymet-CDDP NPs and PEI-
CDDP NPs were able to promote greater platinum uptake into the tumor, and further into 
tumor cells specifically. Because polymet-CDDP NPs and PEI-CDDP NPs showed no 
significant difference in tumor accumulation, it is likely that the improved anticancer 
efficacy of the polymet CDDP NPs can be attributed to synergistic effects between polymet 
and CDDP on H460 NSCLC. As for the accumulation of CDDP in other organs, similar to 
other nano-platforms, the CDDP loaded NPs distributed more in the liver and spleen 
(approximately 20% ID/g) than free CDDP while not significantly different in heart, kidney, 
and lung tissues 24 h post injection (Fig. S3). Due to similar particle size and zeta potential, 
polymet-CDDP NPs and PEI-CDDP NPs presented almost identical biodistribution 
behaviors in vivo.
3.7. Evaluation of systemic toxicity of polymet-CDDP NPs
The clinical use of CDDP is severely limited by systemic toxicities, and many studies are 
ongoing to mitigate the toxicities of CDDP while preserving the anticancer efficacy and dose 
[13,15]. However, polymet-CDDP NPs demonstrated the capacity to induce efficacy 
comparable to CDDP while significantly reducing systemic toxicities. The in vivo toxicity 
herein was evaluated by monitoring the body weight. After 5 total doses at 2.5 mg/kg CDDP 
administered every other day, the free CDDP group showed a significant body weight 
reduction of up to 10% (Fig. 5D). However, animals treated with polymet-CDDP NPs or 
PEI-CDDP NPs exhibited no statistically significant changes in weight to the PBS control.
Hematological parameters and histopathology of major organs (heart, liver, spleen, lung, and 
kidney) were measured 24 h after the last treatment of either PBS, PEI-CDDP NPs, polymet 
NPs, free CDDP or polymet-CDDP NPs to investigate the toxicity. Hematological 
parameters AST, ALT, BUN and creatinine were all within the normal range for PEI-CDDP 
NPs, polymet NPs, polymet-CDDP NPs groups (Fig. 5D, Fig. S5). Additionally, no 
noticeable histological changes were seen in H&E-stained tissue sections of the liver, kidney 
and spleen in these groups (Figs. 5F, S4). Noticeable histological changes were observed in 
H&E-stained kidney tissue sections of free CDDP treated mice, indicating severe 
nephrotoxicity (Fig. 5F). These findings were coincided with the elevated BUN and 
creatinine levels (Fig. 5E). Since the chemotherapy always cause the change of blood cells, 
the count of RBC, WBC, PLT and HGB were checked. The results showed that all groups 
including the free CDDP group were within the normal range (Fig. S5). These studies 
demonstrated that polymet-CDDP NPs have successfully mitigated the prominent toxicities 
of CDDP-based treatment while maintaining significant synergistic therapeutic efficacy. 
Therefore, polymet-CDDP NPs is a promising outlook for enhancing the therapy of NSCLC 
while reducing systemic toxicities of current treatments.
3.8. Mechanism of synergistic effect of polymet and CDDP combo NPs
It is well known that conjugation of PGA to CDDP decreases the anticancer efficacy of 
CDDP, primarily due to its slow release from PGA [19, 33]. Therefore, previous reports 
[14,30] have indicated that treatment with PGA-CDDP alone requires a much higher dose to 
achieve the same anticancer efficacy as that of free CDDP. This result was mirrored in the 
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current study, as the tumor accumulation of PEI-CDDP NPs was significantly higher than 
free CDDP, but the anticancer efficacy of PEI-CDDP NPs was significantly lower over free 
CDDP. This observation provides further evidence that successful anticancer efficacy of 
polymet-CDDP NPs can be attributed to the synergistic effects between CDDP and polymet. 
Herein, the dose of CDDP in polymet-CDDP NPs was only 2.5 mg/kg, 37% lower than 4 
mg/kg required to induce significant anticancer efficacy with PGA-CDDP alone [19,33]. 
Despite this lower dose, results in Fig. 5 indicated polymet-CDDP NPs maintain the best an-
titumor efficiency. Thus, it is hypothesized that the synergy between polymet with CDDP is 
responsible for the successful efficacy even at a lower dose.
Emerging evidence indicates that AMPK is a promising metabolic tumor suppressor and 
target for cancer prevention and therapy [34, 35]. Recent studies have demonstrated the 
antidiabetic drug metformin could act as an AMPK activator and mTOR inhibitor for use as 
a cancer therapeutic [36,37]. Thus, the activity of polymet was examined with respect to its 
role in these two pathways.
It was found that treatment with polymet or polymet-CDDP NPs increased the 
phosphorylation levels of AMPKα in the H460 tumor compared with the PBS group. This 
finding was not observed in PEI-CDDP NPs group (Fig. 6A and B), suggesting that polymet 
is the key factor for activation of the AMPKα pathway. Polymet’s ability to activate the 
AMPKα pathway while simultaneously inhibiting mTOR suggests its mechanism of 
synergy with CDDP. The AMPK pathway is known to intersect with the congogenic Ras/
Phosphatidylinositol 3-kinase (PI3K)/mTOR and extra cellular signal regulated kinase 
(ERK) pathways at multiple points [38,39]. Collectively, it is known that AMPK responds to 
a decrease in cellular ATP by phosphorylating effectors that inhibit mTOR activity. 
Therefore, AMPK activation leads to a subsequent decrease in mTOR activity [40]. In vivo, 
S6K1 or 4E-BP1 phosphorylation is primarily used as readout for mTOR activity. Therefore, 
the effect of polymet and polymet-CDDP NPs on the activity of mTOR and its downstream 
P-p70-s6K, P-4E-BP1 was investigated in this respect (Fig. 6A and B). Analysis indicated a 
significant inhibition of mTOR activity as well as inhibition of its downstream P-p70-s6K 
and P-4E-BP1 compared to the PBS group and PEI-CDDP NPs group. From the western 
blot analysis, it could be concluded that polymet was loaded in polymet NPs and co-loaded 
with CDDP in polymet-CDDP NPs.
Cleaved PARP acts as a reliable marker for the suppression of DNA repair and induction of 
apoptosis [22,41]. During apoptosis, intact PARP is cleaved into a small and large subunit. 
The level of cleaved PARP was further investigated to determine the underlying basis of 
synergy. Fig. 6C and D indicates that the level of cleaved PARP increased in tumors treated 
with polymet-CDDP NPs and was accompanied by a decrease in the level of uncleaved 
PARP. Conclusively, polymet-CDDP NPs exhibited greater efficacy in inhibiting DNA 
repair, leading to intensified apo-ptosis compared to CDDP and polymet in separate NPs.
Separately, high ERCC1 and XPA levels have been implicated to produce resistance to 
platinum based chemotherapy due to their ability to repair DNA damage done by platinum 
adducts [42,43]. Therefore, lower levels of ERCC1 and XPA offer a good prognosis for 
tumor growth inhibition. The effect of combining CDDP and polymet on ERCC1 and XPA 
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was examined via western blot analysis. Results indicated that tumors treated with polymet-
CDDP NPs expressed significantly decreased expression of ERCC1 and XPA in comparison 
to tumors treated with only PEI-CDDP NPs or polymet NPs (Fig. 6C and D). The lowered 
levels of ERCC1 and XPA permitted the use of multiple (5) doses of CDDP without 
incurring significant drug resistance. The ability for sequential dosing without inducing 
resistance showcases yet another advantage to utilizing the combination of CDDP with poly-
metformin.
As indicated in Fig. 7A and B, treatment with polymet alone produces only negligible 
differences in the expression of ERCC1 and XPA. Yet, cells treated with CDDP caused a 
subsequent increase in both ERCC1 and XPA. On the other hand, a combination of CDDP 
and polymet results in the ablation of both ERCC1 and XPA expression to levels lower than 
the PBS control. Furthermore, the level of cleaved PARP displayed a simultaneous increase 
with using the combination. These results serve to reinforce work done in vivo, which 
describes the role combining CDDP and polymet on regulating ERCC1, XPA, and cleaved 
PARP levels. Treatments consisting of both CDDP and polymet delivered simultaneously 
decrease the expression of key DNA repair proteins, inhibiting successful repair of platinum 
DNA adducts and result in the subsequent apoptosis of affected cells. Apoptosis was 
confirmed both by TUNEL and by the increase in cleaved PARP expression, a reliable 
marker for cell apoptosis.
In summary, the combination of CDDP and polymet allows the downregulation of ERCC1 
and XPA, key DNA repair proteins that prevent platinum adduct-based apoptosis. 
Downregulation of ERCC1 and XPA are followed by increased cell apoptosis as determined 
by the increase in level of cleaved PARP and decrease of uncleaved PARP. Simultaneously, 
activity in the AMPK tumor suppressor pathway is significantly augmented by the presence 
of polymet, which working in conjunction with the downregulation of ERCC1 and XPA, 
inhibits tumor proliferation. In addition, further examination into downstream targets 
indicates that the upregulation of AMPK is followed by the decrease of mTOR activity. 
Collectively, these results indicate the mechanism of the synergy between CDDP and 
polymet.
4. Conclusions
In summary, the development of core-membrane NPs capable of co-encapsulating two drugs 
of different physicochemical properties have permitted the creation of a novel anti-cancer 
regimen composed of CDDP and polymeric metformin. By employing the prominent 
synergy between the two drugs, polymet-CDDP NPs have displayed significantly enhanced 
anticancer efficacy in comparison to PBS, polymet NPs and PEI-CDDP NPs. Furthermore, 
the efficacy of polymet-CDDP NPs was statistically equivalent to that of free CDDP. 
However, polymet-CDDP NPs have successfully mitigated the prominent toxicities that 
hamper the clinical application of CDDP, namely nephrotoxicity and significant weight loss. 
Investigations into the mechanisms of the successful anticancer efficacy of polymet-CDDP 
NPs have pointed to a host of reasons for its achievement. High tumor and cellular uptake of 
polymet-CDDP NPs indicate the formulation’s ability to deliver large amounts of drug into 
the tumor. Moreover, active targeting through sigma receptors allows tumor specific delivery 
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on the cellular level. After successful delivery, the synergy between CDDP and polymet 
ensures the limited drug release due to conjugation of CDDP with PGA during formulation 
does not hamper the efficacy of the treatment. Rather, polymet-CDDP NPs displayed the 
greatest anticancer efficacy among all treatment groups. Additionally, in vitro examination 
into the anticancer ability of polymet-CDDP NPs is in accordance with all in vivo studies, 
ensuring the mechanistic basis behind the successful efficacy is accurate. Relative to free 
CDDP and even a PBS control, polymet-CDDP NPs decreased the expression of XPA and 
ERCC-1. Ablating the mechanism of cisplatin induced drug resistance allowed polymet-
CDDP NPs to be delivered in many doses without incurring drug tolerance, a feat that is not 
possible with CDDP alone. Overall, the polymet-CDDP NP platform serves an influential 
role for cancer drug delivery in its ability to co-encapsulate two drugs of differing properties 
for synergistic effects. Furthermore, the platform successfully alleviates the prominent 
toxicities that are the current clinical barrier to further implementation of CDDP as a front 
line anti-cancer therapeutic while maintaining a level of efficacy comparable to CDDP.
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Abbreviations
NSCLC
non-small cell lung cancer
CDDP
cisplatin
polymet
polymeric metformin
AMPK
AMP-activated protein kinase
mTOR
mammalian target of rapamycin
ERCC1
excision repair cross-complementation group 1
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IV
intravenous
PK
pharmacokinetic
NPs
nanoparticles
RES
reticuloendothelial system
PGA
polyglutamic acid
PEI
polyethylenimine
EDC
ethylene dichloride
NHS
N-hydroxysuccinimide
MTT
3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide
DAPI
4′,6-diamidino-2-phenylindole
DIPEA
N,N-Diisopropylethylamine
DOTAP
2,3-dioleoyloxy-propyl)-trimethylammonium
RIPA
Radio-Immunoprecipitation Assay
BCA
Bicinchoninine acid
HRP
horseradish peroxidase
DSPE-PEG2000
1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethyleneglycol-2000)]
(ammonium salt)
DSPE-PEG-AA
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DSPE-PEG-aminoethyl anisamide
TUNEL
TdT-dependent dUTP-biotin nick end labeling
GAPDH
glyceraldehyde-phosphate dehydrogenase
XPA
xeroderma pigmentosum complementation group A
PARP-1
poly ADP-ribose polymerase-1
PBS
phosphate-buffered saline
1H NMR
nuclear magnetic resonance
DLS
dynamic light scattering
PDI
polydispersity index
TEM
transmission electron microscope
ICP-MS
inductively coupled plasma mass spectrometry
BUN
blood urea nitrogen
AST
aspartate aminotransferase
ALT
alanine aminotransferase
RBC
red blood cells
WBC
white blood cells
PLT
platelets
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HGB
hemoglobin
HCT
hematocrits
PIC
protease inhibitor cocktail
SDS-PAGE electrophoresis
sodium dodecyl sulfate polyacrylamide gel electrophoresis
PVDF
polyvinylidene difluoride
BSA
Bovine Serum Albumin
MALDI-TOF-MS
matrix-assisted laser desorption/ionization time of flight mass spectrometry
MTD
maximum tolerable dose
PI3K
phosphatidyl inositol 3 kinase
ERK
extracellular signal regulated kinase
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Fig. 1. 
Preparation and characteristic for polymet-CDDP NPs. (A) Synthesis scheme of polymet. 
(B) Synthesis scheme of PGA-CDDP. (C) Preparation of polymet-CDDP NPs.
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Fig. 2. 
The optimization of polymet-CDDP core and NPs. (A) Effects of different molar ratio of 
polymet (unit of metformin) to CDDP on the size and zeta potential of polymet-CDDP core. 
Ratios were calculated according to the metformin unit of polymet. (B) Effects of different 
molar ratio of DOTAP to CDDP on the size and zeta potential of polymet-CDDP NPs. (C) 
Representative TEM image of polymet-CDDP NPs.
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Fig. 3. 
Cellular uptake and release of CDDP (based on Pt) from polymet-CDDP NPs. (A) In vitro 
uptake of CDDP in free CDDP, PGA-CDDP, polymet-CDDP NPs, and PEI-CDDP NPs at 
37 °C for 4 h in H460 cells. (B) Cumulative in vitro release kinetics of CDDP, PGA-CDDP, 
polymet-CDDP NPs, PEI-CDDP NPs in PBS (pH 7.4, Cl− concentration: 100 mM) at 37 °C. 
ns: no significance; **P < 0.01, ***P < 0.001 (n = 3).
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Fig. 4. 
Synergy between CDDP and polymet on H460 cells. The corresponding combination index 
(CI) vs Fa plots of polymet-CDDP NPs and free CDDP were shown (A). IC50 of free CDDP, 
PGA-CDDP, polymet-CDDP NPs (molar ratio of CDDP and polymet at 1∶1), polymet NPs 
and PEI-CDDP NPs (molar ratio of CDDP and PEI at 1∶1) were shown (B). Ratios were 
calculated according to the unit of polymet or PEI. ns: no significance, **P < 0.01 (n = 3).
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Fig. 5. 
Tumor inhibition effects and systemic toxicity of free CDDP, polymet-CDDP NPs, polymet 
NPs and PEI-CDDP NPs on H460 tumor–bearing mice. (A) H460 tumor–bearing mice were 
injected intravenously Q.O.D 5 times at a dose of 2.5 mg/kg CDDP or the corresponding 
polymet quantity in all the treatment groups. Arrows indicate time of injection. The tumor 
volumes were measured every day. (B) Visual observations of the H460 tumor sizes in each 
treatment group at the end time point. Tumor weights were measured 24 h after the final 
injection. (C) TUNEL assay on H460 tumor cells after treatment with different formulations 
in vivo. The percentage denotes the average percentage of TUNEL positive cells (green). 
Five randomly selected microscopic fields were quantitatively analyzed using Image J. (D) 
Effect of free CDDP, polymet-CDDP NPs, polymet NPs and PEI-CDDP NPs on body 
weight of H460 tumor– bearing mice. The body weights were measured every day. Data 
represents the mean ± SEM (n = 4–6 per group). **P < 0.01, ***P < 0.001. ns: no 
significance. (E) Kidney functional parameters, blood urea nitrogen (BUN) and creatinine. 
Data represents the mean ± SEM (n = 4–6 per group). **P < 0.01, ***P < 0.001. ns: no 
significance. (F) H&E staining of kidney tissue from H460 tumor–bearing mice that 
received 5 doses of treatment. Arrows indicate tubular cell atrophy.
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Fig. 6. 
Western blot analysis of H460 tumor protein levels after five injections of polymet-CDDP 
NPs, polymet NPs and PEI-CDDP NPs. (A) p-mTOR, p-p70S6k, p-4E-BP1, p-AMPKα 
protein levels were evaluated. (B) Quantification of the protein level of p-mTOR, P-p70-s6, 
P-4E-BP1 and p-AMPKα which were concerned with the polymet pathway. Both polymet 
NPs and polymet-CDDP NPs could decrease p-mTOR, p-p70S6k, and p-4E-BP1 as well as 
increase the p-AMPKα. (C) ERCC-1, XPA, PARP and Cleaved PARP protein levels were 
evaluated. Polymet combined with CDDP into NPs will decrease the XPA and ERCC-1 and 
increased the cleaved PARP. (D) Quantification of the protein level of ERCC-1, XPA, PARP 
and Cleaved PARP. Comparing PEI-CDDP NPs, polymet-CDDP NPs could decrease 
ERCC-1, XPA and increase Cleaved PARP more efficiently. All quantifications were done 
by using Image J. Data are mean ± S.D. (n = 3).
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Fig. 7. 
Western blot analysis of protein levels after treating 24 h with polymet, CDDP and their 
combination (combo) on H460 tumor cells in vitro. (A) ERCC-1, XPA, PARP and cleaved 
PARP protein levels were evaluated. In vitro test certified that polymet combined with 
CDDP will decrease the XPA and ERCC-1 and increased the Cleaved PARP. The 
concentration of polymet and free CDDP were 1 μM and combo including both 1 μM 
polymet (calculated according to the metformin unit of polymet) and 1 μM free CDDP. (B) 
Quantification of the protein level using image J. Data are mean ± S.D. (n = 3).
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Table 1
Sizes, PDI and zeta potentials of different cores and final nanoparticles (n = 3).
Diameter (nm) PDI Zeta potential (mv)
polymet-CDDP Corea 132 ± 2 0.2 ± 0.0 −35 ± 1
polymet-CDDP NPsb 151 ± 1 0.2 ± 0.0 49 ± 1
PEI-CDDP corec 150 ± 3 0.38 ± 0.1 −30 ± 0
PEI-CDDP NPsd 189 ± 2 0.2 ± 0.0 48 ± 1
a
Molar ratio of CDDP to PGA = 1∶4.
b
Molar ratio of CDDP to polymet = 1∶1.
c
Molar ratio of DOTAP to CDDP = 10∶1.
d
Molar ratio of DOTAP∶Cholesterol∶DSPE-PEG∶DSPE-PEG-AA = 1∶1∶0.12∶0.11.
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